Assessing the relationship of patient global assessment of disease activity and health related quality of life by SF-36 with other patient-reported outcomes in rheumatoid arthritis: post hoc analyses of data from phase 3 trials of baricitinib (Journal of Rheumatology, 2022)

(untitled) - Strand, V; Sebba, A; Scardo, S; Quebe, A; Zaremba-Pechmann, L; Taylor, P; Sholter, D